Literature DB >> 25922404

Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship.

Teena Chopra1, Ellie J C Goldstein2.   

Abstract

Across the United States, the baby boomers are entering into their elderly years. As they are America's largest generation to do so to date, their need for care will greatly affect nursing homes, long-term care facilities, and long-term acute-care hospitals (LTACHs). Unfortunately, the rise of Clostridium difficile infection (CDI), particularly in extended-care facilities, might become the biggest obstacle in their care. Elderly extended-care-facility residents are at an elevated risk of CDI simply due to their advanced age and the fact that they are receiving care in an extended-care facility. LTACHs experience a high incidence rate of CDI, and these infections can lead to major complications for a patient's health. Other factors that contribute to higher risk for CDI include receiving multiple courses of antibiotics, longer length of antibiotic treatment, and previous CDI. Although this obstacle to proper care is great, some simple solutions are available to healthcare providers. Probiotics may help improve natural immunity in patients, and strict adherence to antimicrobial stewardship standards could help reduce this serious bacterial threat.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  C. difficile colonization; C. difficile infection; antibiotic stewardship; long-term care facilities; probiotics

Mesh:

Substances:

Year:  2015        PMID: 25922404     DOI: 10.1093/cid/civ053

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Importance of Molecular Methods to Determine Whether a Probiotic is the Source of Lactobacillus Bacteremia.

Authors:  Alla Aroutcheva; Julie Auclair; Martin Frappier; Mathieu Millette; Karen Lolans; Danielle de Montigny; Serge Carrière; Stephen Sokalski; William E Trick; Robert A Weinstein
Journal:  Probiotics Antimicrob Proteins       Date:  2016-03       Impact factor: 4.609

Review 2.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

3.  AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge.

Authors:  Matthew M Guilleman; Brenna A Y Stevens; Laura P Van Lieshout; Amira D Rghei; Yanlong Pei; Lisa A Santry; Brad Thompson; Sarah K Wootton
Journal:  Gene Ther       Date:  2021-02-19       Impact factor: 5.250

4.  Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease.

Authors:  Jennifer K Spinler; Aaron Brown; Caná L Ross; Prapaporn Boonma; Margaret E Conner; Tor C Savidge
Journal:  Anaerobe       Date:  2016-05-11       Impact factor: 3.331

5.  Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing.

Authors:  Bradley T Endres; Kierra M Dotson; Kelley Poblete; Jacob McPherson; Chris Lancaster; Eugénie Bassères; Ali Memariani; Sandi Arnold; Shawn Tupy; Conner Carlsen; Bonnie Morehead; Sophia Anyatonwu; Christa Cook; Khurshida Begum; M Jahangir Alam; Kevin W Garey
Journal:  Infect Control Hosp Epidemiol       Date:  2018-09-26       Impact factor: 3.254

Review 6.  Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections.

Authors:  Lynne Vernice McFarland; Metehan Ozen; Ener Cagri Dinleyici; Shan Goh
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

7.  Predictors of Clostridium difficile infection and predictive impact of probiotic use in a diverse hospital-wide cohort.

Authors:  Martha L Carvour; Shane L Wilder; Keenan L Ryan; Carla Walraven; Fares Qeadan; Meghan Brett; Kimberly Page
Journal:  Am J Infect Control       Date:  2018-09-08       Impact factor: 2.918

8.  Predominance of Clostridium difficile Ribotypes 017 and 078 among Toxigenic Clinical Isolates in Southern Taiwan.

Authors:  Yuan-Pin Hung; I-Hsiu Huang; Hsiao-Ju Lin; Bo-Yang Tsai; Hsiao-Chieh Liu; Hsiu-Chuan Liu; Jen-Chieh Lee; Yi-Hui Wu; Pei-Jane Tsai; Wen-Chien Ko
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

Review 9.  Infection prevention and control of Clostridium difficile: a global review of guidelines, strategies, and recommendations.

Authors:  Evelyn Balsells; Teodora Filipescu; Moe H Kyaw; Camilla Wiuff; Harry Campbell; Harish Nair
Journal:  J Glob Health       Date:  2016-12       Impact factor: 4.413

10.  Burden of Nursing Home-Onset Clostridium difficile Infection in the United States: Estimates of Incidence and Patient Outcomes.

Authors:  Jennifer C Hunter; Yi Mu; Ghinwa K Dumyati; Monica M Farley; Lisa G Winston; Helen L Johnston; James I Meek; Rebecca Perlmutter; Stacy M Holzbauer; Zintars G Beldavs; Erin C Phipps; John R Dunn; Jessica A Cohen; Johannetsy Avillan; Nimalie D Stone; Dale N Gerding; L Clifford McDonald; Fernanda C Lessa
Journal:  Open Forum Infect Dis       Date:  2016-01-18       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.